Risk in CNS drug discovery: Focus on treatment of Alzheimer's disease

BMC Neuroscience

Volumn 9, Issue SUPPL. 3, 2008, Pages

  Fred, J Fred ^a  

^a MDS Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINESTERASE INHIBITOR; LONG ACTING DRUG; MEMANTINE;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CONFERENCE PAPER; DECISION MAKING; DEGENERATIVE DISEASE; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG MONITORING; DRUG PENETRATION; DRUG QUALITY; DRUG RESEARCH; DRUG TRANSPORT; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; NONHUMAN; PATIENT SAFETY; POLYPHARMACY; RISK MANAGEMENT;

EID: 57649136762     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-9-s3-s1     Document Type: Conference Paper

References (7)

1. Kola I Landis J Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004, 3:711-715 10.1038/nrd1470 15286737
2. Parexel's Pharmaceutical R&D Statistical Sourcebook http://www.parexel.com/products_services/publications.asp
3. US Food and Drug Administration Innovation Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products 2004 http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
4. Roses A Genome-based pharmacogenetics and the pharmaceutical industry Nat Rev Drug Discov 2002, 1:541-549 10.1038/nrd840 12120260
5. Frank R Hargreaves R Clinical biomarkers in drug discovery and development Nat Rev Drug Discov 2003, 2:566-580 10.1038/nrd1130 12838269
6. Lang P Yeow K Nichols A Scheer A Cellular imaging in drug discovery Nat Rev Drug Discov 2006, 5:343-356 10.1038/nrd2008 16582878
7. Pritchard JF Jurima-Romet M Reimer M Mortimer E Rolfe B Cayen M Making better drugs: Decision gates in non-clinical drug development Nat Rev Drug Discov 2003, 2:542-553 10.1038/nrd1131 12815380